IDEAS home Printed from https://ideas.repec.org/a/oup/scippl/v38y2011i5p338-348.html
   My bibliography  Save this article

High-tech hopes: policy objectives and business reality in the biopharmaceutical industry

Author

Listed:
  • Juha Tuunainen

Abstract

This paper analyses Finnish biotechnology policy and combines this with a look at the evolution of a university spin-off company's business models. It offers a rare grass-roots perspective on policy implementation and further develops the business model concept. Business models should be understood as future-oriented ‘where-to’ artefacts that can be used to develop business activities to meet future economic demands. Concerning policy implementation, this paper highlights the obstacles that small companies encounter when they operate as part of the global knowledge-based economy, as well as describing the solutions that may be developed to overcome such hurdles. The paper concludes that the business activities of high-tech companies might be supported by: first, strengthening the public support systems of young companies; second, developing the business models of those companies so as to gain income early; and finally, focusing national efforts on building new industries in areas where some industrial tradition already exists. Copyright , Beech Tree Publishing.

Suggested Citation

  • Juha Tuunainen, 2011. "High-tech hopes: policy objectives and business reality in the biopharmaceutical industry," Science and Public Policy, Oxford University Press, vol. 38(5), pages 338-348, June.
  • Handle: RePEc:oup:scippl:v:38:y:2011:i:5:p:338-348
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.3152/030234211X12960315267570
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Michelle Marie Lockhart & Zaheer-Ud-Din Babar & Christopher Carswell & Sanjay Garg, 2013. "New Zealand’s Drug Development Industry," IJERPH, MDPI, vol. 10(9), pages 1-13, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:scippl:v:38:y:2011:i:5:p:338-348. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Oxford University Press (email available below). General contact details of provider: https://academic.oup.com/spp .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.